Stockreport

Dimension Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

DIMENSION THERAPEUTICS  (DMTX) 
US:NASDAQ Investor Relations: investors.dimensiontx.com
PDF Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa an [Read more]